Heat Biologics Protocol No. HS130 -001 A Phase I Study of HS -130 in combination with HS-110 in patients with solid tumors HS130- 001 59 of 60 Version 2.0 - 11 Feb 2020 Confidential - Entire Page APPENDIX II - Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Available from the Cancer Therapy Evaluation Program website: https: //ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm Heat Biologics Protocol No. HS130 -001 A Phase I Study of HS -130 in combination with HS-110 in patients with solid tumors HS130- 001 60 of 60 Version 2.0 - 11 Feb 2020 Confidential - Entire Page APPENDIX III - Summary of Changes Protocol Change Affected Section(s) Numbers Section Titles Version 2.0 , dated 11 February 2020 Update to Sponsor address. Title Page, Synopsis, Section 1.2 Title Page, Synopsis, Sponsor Update to Medical Monitor email address. Section 1.3 Title Page, Medical Monitor ‘Immunological effect’ changed from secondary endpoint to exploratory endpoint Synopsis, Sections 3.0, 9.2.2, 9.2.3 Synopsis, Trial Objectives and Purpose, Secondary Endpoints, Exploratory Endpoints Clarification that the DLT observation period is four weeks. Synopsis, 6.1.2 Synopsis, Dose -Limiting Toxicity Clarification that patients who refuse standard of care may be eligible Synopsis, 5.1 Synopsis, Inclusion Criteria Clarification of eligibility regarding washout of radiation for curative/treatment (4 weeks) and palliative radiation (2 weeks) Synopsis, 5.2 Synopsis, Exclusion Criteria Updated Study ‘withdraw criteria’ categories to align with C DISC reporting categories 5.4 Withdraw Criteria Clarificat ion of when patients will be declared “lost to follow -up” 5.4.1 Withdrawn Subjects Clarification of verbiage regarding dose reductions 6.1.1 Dose Escalation Scheme Clarification that AEs occurring prior to C1D1 may be reportable if dire ctly related to a study procedure 8.1.2.1 Adverse Events Clarification that, in general, Disease Progression and/or Deaths related to Disease Progression are not considered to be Serious Adverse Events 8.1.2.4 Serious Adverse Events Clarification that SAEs occurring prior to dosing on Day 1 may be reportable if directly related to a study procedure 8.1.2.7 Reporting of Serious Adverse Events Removed Pain Assessment as part of the safety section 9.3 Safety Added a summary of protocol changes from previous versions Appendix III Summary of Changes